WM clinical research study
seeks volunteers
Clinical research studies help researchers learn about potential treatments, called investigational or study drugs. A clinical research study, or clinical trial, is now enrolling people living with Waldenström Macroglobulinemia (WM) who have a CXCR4 genetic variant, or mutation. People with the CXCR4 variant do not respond as well to existing BTK inhibitor treatments for WM, such as ibrutinib.
About the Study
This clinical research study will help researchers answer questions about the study drug, which is called mavorixafor.
Mavorixafor is an investigational oral medication taken as a capsule.
This is a Phase 1b study, which means researchers want to know what dosage of mavorixafor, (the study drug) is safe.
The study drug will be taken in combination with ibrutinib, an FDA-approved treatment for WM.
The study is being conducted as part of a collaboration with The Leukemia & Lymphoma Society to help advance the development of mavorixafor for the treatment of WM.
Who can join?
- Adults age 18+
- WM diagnosis with MYD88 and CXCR4 genetic variants
- You may need to meet more criteria in order to join the study.
To learn more, visit ClinicalTrials.gov and search for NCT04274738
Why participate in a clinical study?
- More treatment options are needed for people living with WM.
- People who join this clinical study may help researchers understand more about WM and potential treatments.
- Clinical studies are required to make sure a medicine is safe and works before it is approved by the FDA as a treatment option.
- There is no cost to join the study, and expenses for medical care and travel are reimbursed by X4 Pharmaceuticals, the study sponsor.
